

1 **Title:** Effects of intermittent claudication due to arterial disease on pain-free gait.

2 **Authors:**

3 **Corresponding author: Dr Eftychia Evangelopoulou**¹ University of Salford

4 Centre for Health, Sport and Rehabilitation Sciences Research, University of Salford, Salford, UK

5 Email: effyevans@hotmail.com

6

7

8 **Professor Richard K Jones** School of health & Society, University of Salford

9 Centre for Health, Sport and Rehabilitation Sciences Research, University of Salford, Salford, UK

10

11

12 Email: r.k.jones@salford.ac.uk

13

14 **Dr Mohideen Jameel** Wigan and Leigh NHS Foundation Trust, UK

15 Department of Vascular Surgery, Royal Albert Edward Infirmary, Wigan, UK

16 Email: deenjam@gmail.com

17

18

19

20

21 **Mr Peter Boyd** Wigan and Leigh NHS Foundation Trust, UK

22 Department of Vascular Surgery, Royal Albert Edward Infirmary, Wigan, UK

23 Email: peteb2006@tiscali.co.uk

24

25

26

27 **Professor Chris Nester PhD BSc (Hons)** School of health & Society, University of Salford

28 Centre for Health, Sport and Rehabilitation Sciences Research, University of Salford, Salford, UK

29

30 Email: c.j.nester@salford.ac.uk

¹ Permanent address: Flat 28, 2Ridway St., M47LB, Manchester, UK

31 **Funding sources:** This work was partly funded by the Wrightington, Wigan and Leigh NHS
32 Foundation Trust.

33

34 Word count:

35 Abstract: 250

36 Article: 3663

37

38 Abstract

39

40 *Introduction:*

41 Studies of intermittent claudication gait report inconsistent outcomes. Changes in gait are often
42 attributed to degradation of calf muscles, but causation has not been proven through real-time
43 electromyographic data. Neither have effects of walking speed been fully considered. This study aimed
44 to investigate the effect of intermittent claudication on kinematics, kinetics and muscle activity during
45 pain-free gait.

46 *Methods:*

47 18 able bodied individuals and 18 with intermittent claudication walked at their preferred speed while
48 lower limb kinematic, kinetic and electromyography data were collected.

49 Findings:

50 People with intermittent claudication walk slower and with reduced step length. Internal ankle
51 plantarflexion moment ($P=0.004$, effect size=0.96) and ankle power generation ($P<0.001$, effect size=1.36)
52 in late stance were significantly reduced for individuals with intermittent claudication. Significant moment
53 and power reductions at the knee and power reduction at hip occurred in early stance, with similar
54 reductions in early and late stance for ground reaction forces. Peak electromyography of soleus activity
55 was significantly reduced in late stance ($P = 0.01$, effect size = 1.1, $n=13$). Effects were independent of
56 walking speed.

57 Interpretation:

58 Reductions in ankle plantarflexion moments and power generation were consistent with reduced soleus
59 electromyography activity and reduced peak vertical ground reaction forces during late stance. These

60 effects are not due to a reduced walking speed. Changes in knee and hip function are also unrelated to
61 walking speed. These outcomes provide a platform for the design and evaluation of interventions that
62 seek to restore normal walking and improve pain-free walking distances for people with intermittent
63 claudication.

64

65 Key words: intermittent claudication, gait, moment, pain-free

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84 1. Introduction

85 Peripheral arterial disease affects 202 million people worldwide [1]; 20 million people in Europe, 8-10
86 million in north America, 10% of individuals over 65 years of age and 20% of those over 80 [2]. It is caused
87 by atherosclerosis resulting in stenosis or occlusion of peripheral arteries which reduces the supply of
88 blood and thereby oxygen and nutrients to peripheral tissues. During walking, blood flow in skeletal
89 muscles increases to supply the higher oxygen demand. In peripheral artery disease, this increase cannot
90 be achieved due to arterial occlusion resulting in lack of oxygen in muscles during walking. This causes
91 cramping pain in the leg, most commonly in the calf. This pain typically occurs after walking short distances
92 (e.g. less than 200m) and requires the individual to halt. Pain resolves after a few minutes rest but returns
93 in a repeatable pattern during further walking, and is thus called intermittent claudication (IC). This affects
94 50% of individuals with arterial disease [3] impairs mobility and quality of life [4] and warrants surgery in
95 many cases [5-6].

96 Several studies [7-13] have attempted to characterise gait in patients with IC. . However, despite the
97 underlying physiological mechanism in IC being muscle activity and the associated demand for blood,
98 fewer studies have reported muscle activity during gait for this patient group [13,14]. Gommans et al
99 (2016), reported that tibialis anterior and medial gastrocnemius activity were the same as in healthy age-
100 matched controls [13]. This finding appears to be in contradiction with the reductions in moment at the
101 ankle and knee reported by Koutakis et al [11,12]. A similar contradiction appears between kinetic and
102 kinematic studies and Bartolo et al (2019) who identified an increase in EMG muscle activity in many major
103 lower limb muscles including the gastrocnemius and tibialis anterior [14]. In stationary studies, King et al
104 (2015) identified that the soleus muscle contributes more to plantarflexion in both claudicating and
105 asymptomatic limbs of individuals with PAD-IC compared to controls [15]. Although this is supported by
106 muscle fibre changes observed in this group, it still does not provide a direct link to the kinetic results
107 observed in other studies. The present study aimed to more uniformly investigate the link between muscle
108 activity and the kinetics and kinematics of pain-free PAD-IC gait. It also aims to add to the existing research
109 so that a more robust picture of PAD-IC gait and its potential musculature-based causes can be
110 established.

111 Identifying any changes in gait, and especially muscle activity, is important because it should help inform
112 the purpose of physical therapy interventions, such as exercise programs and therapeutic footwear. For
113 example, footwear and orthoses that reduce calf muscle activity have been advocated for people with IC
114 [6-17], but optimising these designs is hampered by an incomplete description of gait in IC.

115 As a forerunner to future work on gait interventions for IC, this study aimed to investigate the effects of
116 IC on gait kinematics, kinetics and muscle activity.

117

118 1. Methods

119 Following ethical approval (14/LO/0382), 18 individuals with IC were recruited from local health services
120 and 18 healthy and aged matched controls recruited from the same settings and the University
121 community. Participants with IC were aged 50 years or over had a formal diagnosis confirmed by a
122 Consultant Vascular surgeon (at least 3 months prior to participation). Diagnosis was based on colour-flow
123 duplex scan, medical history, absence or reduction in foot pulses, and an ankle brachial pressure index
124 (ABPI) of less than 0.8. They were able to walk for a minimum of 100m or perform 2 minutes of continuous
125 walking unaided (Fontane scale II) [18]. Exclusion criteria were an active or a prior foot ulcer, significant
126 foot deformities necessitating use of foot orthoses, complete neuropathy in their feet, surgery in the
127 previous six months, pain in their lower limbs or back with a cause unrelated to peripheral arterial disease,
128 painful knee, ankle or hip osteoarthritis, total reliance on walking aids, prior lower limb joint replacement,
129 and morbid obesity (BMI>35). Healthy participants were excluded if they presented with any of the
130 following: significant pain in the legs when walking, prior injury to the legs or spine, diabetic neuropathy,
131 foot deformities (e.g. club foot, amputation of toes), prior joint replacement or major orthopaedic
132 surgery.

133

134 2.1 Data collection

135 Participants wore shorts and t-shirt, and sites for EMG electrodes over tibialis anterior, medial
136 gastrocnemius, lateral gastrocnemius and soleus muscles were prepared according to SENIAM guidelines
137 [19]. Electrodes were connected to a Noraxon Telemetry system (TeleMyo 2400T G2, Noraxon U.S.A. Inc)
138 and wires secured with bandages. Reflective markers were placed on the lower limb and pelvis following
139 a CAST marker set-up (fig 1). Shoes were standardised and of an oxford style.

140

141 *Figure 1: Marker set up: 2nd toe, 1st and 5th distal metatarsal head, 1st (1PMT) and 5th proximal metatarsal*
142 *head, 3 heel markers, medial and lateral malleolus, cluster of 4 shank markers, medial and lateral femoral*
143 *tuberosity, cluster of 4 thigh markers, right and left greater trochanter, right and left anterior and posterior*
144 *superior iliac spine.*

145

146 Participants practised walking and their speed was recorded using timing gates to derive mean speed and
147 a +/-5% tolerance. Participants then walked, at their preferred speed, as kinematic, (15 camera Qualysis
148 system, Gothenburg, Sweden), ground reaction (400x600, AMTI Watertown, MA, USA) and EMG data was
149 collected. Five successful walks were recorded for each participant. A walk was successful if the participant
150 placed their feet on the force plates (the most affected limb only for IC participants) and walking speed
151 remained within +/-5% of their mean speed. Healthy counterparts did not walk at speeds matched to the
152 IC participants but speed was accounted for statistically.

153

154 2.2 Data processing

155 Markers were defined within Qualysis Track Manager and processed alongside force plate data in Visual
156 3D. The CAST marker set technique [20] was used. Rigid clusters of four non-orthogonal markers were
157 placed over the lateral shank, lateral thigh and sacrum to track kinematics of each segment in six degrees
158 of freedom. Eight retroreflective markers (fig 1) were placed onto each shoe type using double sided tape.
159 The foot was modelled as a rigid, single segment. A static calibration trial was collected, for each
160 experimental condition, in which retroreflective markers were placed on bony landmarks to specify the
161 location of the lower limb joints in relation the clusters and to approximate joint centres. Ankle and knee
162 joint centres were calculated as midpoints between the malleoli and femoral epicondyles, respectively.
163 The hip joint centre was calculated using the regression model based on the anterior and posterior
164 superior iliac spine markers [21]. In Visual 3D (C-Motion, Rockville, Maryland, USA), joint kinematics were
165 calculated using an X–Y–Z Euler rotation sequence equivalent to the joint coordinate system [22] and joint
166 kinetic data were calculated using three-dimensional inverse dynamics. Moments were then normalised
167 to body mass. Marker data was filtered using a 4th order Butterworth filter with a cut-off of 12 Hz. Kinetic
168 data was low pass filtered with a cut-off of 25Hz. The data for each curve was then exported and ordered
169 in Matlab (Mathworks, Natick, Massachusetts, USA) and exported to excel (Microsoft Excel 2013,
170 Redmond, Washington, USA).

171 EMG signals were exported in their raw form to Matlab. Within Matlab, the signals were full-wave
172 rectified, high pass filtered at 20 Hz, low pass filtered at 500 Hz and then filtered using an RMS envelope
173 with a time window of 80. The methodology of filtering and cut-off values were as indicated by DeLuca
174 (2010) [23]. The signal was synchronised with the gait cycle, using a manual sync pulse which was activated

175 during data collection. During Matlab processing, this pulse was used to synchronise the muscle signals
176 with the duration of the gait cycle and the signal that was captured outside the gait-cycle of interest was
177 deleted. Matlab processing was made using a custom script. The relevant signal for each muscle was then
178 exported to excel. Within excel, the average mean was calculated for each muscle and all trials were
179 normalised to this mean value for each muscle and each participant, during stance phase as in Burden &
180 Barlett (1999) [24].

181 For each participant the mean peaks and troughs for each outcome measure were computed as the
182 average of 5 trials. The outcome measures were: maximum and minimum angle, moment and power at
183 the ankle, knee and hip of the stance limb, peak ground reaction force (GRF) in the anterior/posterior,
184 medial/lateral and vertical directions and maximum EMG activity during stance for the medial and lateral
185 gastrocnemius, the soleus and tibialis anterior muscles, normalised to the mean stance activity of each
186 muscle.

187

188 2.3 Statistical analysis

189 Independent t-tests were implemented via SPSS (Version 23, IBM Corporation, Chicago, USA) to
190 investigate any difference between individuals with IC and healthy counterparts. If data were found not
191 to follow a normal distribution (normality test in SPSS) a non-parametric Wilcoxon test was used. A
192 univariate analysis of variance was conducted with speed as a covariate, to determine the effect of speed
193 on the kinematic, kinetic and EMG characteristics of IC gait.

194

195 2. Results

196 Demographics and temporal gait characteristics of both groups are detailed in table 1. Average speed
197 ($P<0.001$) and step length ($P=0.019$) were significantly reduced by 20% and 12.7% respectively for
198 individuals with IC.

199

200 Table 1: Participant demographics and temporal-spatial parameters.

201

202 EMG data was available from 13 of the 18 participants with IC and 13 controls. In the remaining
203 participants there was occasional EMG system failure and too few trials to use This is due to the study

204 results being part of a larger data collection session which included the use of an orthotic. In patients
205 where EMG signals were compromised due to electrode movement whilst wearing the orthotic, all EMG
206 data for that participant was discounted. This has led to a lower EMG sample size compared to the sample
207 size for kinematic/kinetic data.

208

209 3.1 Ankle

210 The peak internal ankle plantarflexion moment in late stance was reduced in cases of IC ($P=0.006$). Ankle
211 power was significantly reduced for participants with IC both in late ($P<0.001$) and early ($P=0.018$) stance
212 (fig 2a). After adjusting for speed, only the internal ankle plantarflexion moment and ankle power in late
213 stance remained significantly reduced ($P=0.030$; $P=0.022$), and speed did not explain a significant amount
214 of the variance ($P=0.241$; $P=0.092$) (table 2).

215

Figure 2: 2a) Internal ankle moment of individuals with IC (dotted line) and healthy individuals (solid line) during stance. (+ve moment = internal dorsiflexion moment) 2b) Internal knee moment in IC (dotted line) and healthy (solid line) groups during stance. (+ve moment = internal extension moment) 2c) Internal hip in IC (dotted line) and healthy (solid line) groups during stance. (+ve moment = internal extension moment)

216

217 Table 2: Mean, standard deviation and P values for ankle angle ($^{\circ}$), ankle moment (Nm/Kg) and ankle
218 power (W/Kg) in IC and healthy groups. * = Significant difference when adjusted for speed.

219

220 3.2 Knee

221 The internal knee flexion moment was significantly reduced at initial contact in the IC group ($P=0.009$)
222 (fig 2b). Knee power absorption was reduced in both late and early stance ($P=0.002$) ($p P=0.001$) and
223 knee power generation in mid-stance was also significantly reduced ($P=0.047$). When adjusted for
224 speed, only knee power absorption in early stance was significantly reduced compared to healthy
225 controls ($P=0.022$) and walking speed did not explain a significant amount of the variance ($P=0.225$)
226 (table 3).

227

228 Table 3: Mean peaks, standard deviation and P values for knee angle ($^{\circ}$), knee moment (Nm/Kg) and
229 knee power (W/Kg) in IC and healthy groups. * = Significant differences when adjusted for speed.

230

231 3.3 Hip

232 Both the internal extension moment in early stance and the internal flexion moment in late stance were
233 reduced in individuals with IC (fig 2c). Hip power absorption in early stance ($P < 0.001$) and power
234 generation in early stance ($P = 0.024$) were also significantly reduced compared to healthy controls.

235

236 After adjusting for speed, only hip power absorption in early stance was significantly reduced ($P < 0.001$)
237 and speed did not explain a significant amount of the variance ($P = 0.372$) (table 4).

238

239 Table 4: Mean peaks, standard deviation and P values for hip angle ($^{\circ}$), hip moment (Nm/Kg) and hip power
240 (W/Kg) in IC and healthy groups. * = Significant differences when adjusted for speed.

241

242 3.4 EMG

243 The increase from mean to maximum EMG activity, during stance, was reduced for lateral gastrocnemius
244 (by $> 22\%$) ($P = 0.016$) and soleus (by $> 19\%$) ($P = 0.010$) in the 13 participants with IC, (table 5) (fig 3) (un-
245 normalised IC means were lower than Healthy counterparts). When adjusted for speed, only soleus
246 activity remained significantly reduced (adjusted means Healthy: 3.58 times of avg. mean, IC: 2.67 times
247 of avg. mean; $P = 0.26$).

248

Figure 3: 3a) Average lateral gastrocnemius activity in IC (dotted line) and healthy (solid line) groups during stance. EMG normalised using the mean dynamic method. 3b) Average soleus activity in IC (dotted line) and healthy (solid line) groups during stance. EMG normalised using the mean dynamic method.

249

250 Table 5: Mean, standard deviation and P value of peak EMG (expressed relative to each group's EMG
251 mean) in IC and healthy groups. * = Significant differences when adjusted for speed

252

253 3.5 Ground Reaction Force

254 Maximum posterior ($P < 0.001$) and anterior ($P < 0.001$) GRF were significantly reduced in IC gait compared
255 to the healthy group . Maximum lateral GRF in early stance ($P = 0.002$) and maximum vertical GRF in early
256 and late stance were also significantly reduced ($P = 0.002$; $P = 0.045$; $P < 0.001$) (table 6).

257

258 Table 6: Mean peak, standard deviation and P value for GRF (*body weight) in in IC and healthy groups.

259 * = Significant differences when adjusted for speed.

260

261 Once adjusted for speed, late stance vertical GRF, maximum posterior and anterior GRF, and lateral GRF
262 in early stance all remained significantly lower for individuals with IC (table 6). Speed was not found to
263 explain a significant amount of the variance for any GRF variables ($P > 0.05$).

264

265 3. Discussion

266

267 When taken in conjunction with previous literature, statistically significant findings (after adjusting for
268 walking speed) confirm that the key points of difference between gait affected by IC and that of healthy
269 older adults are:

- 270 • Reduced internal ankle plantarflexion moment and ankle power generation in late stance
- 271 • Reduced internal knee flexion moment at initial contact and knee power absorption in early
272 stance
- 273 • Reduced hip power absorption in early stance
- 274 • Reduced peak posterior and lateral ground reaction force in early stance
- 275 • Reduced peak anterior and vertical ground reaction force in late stance
- 276 • Reduced increase in EMG activity of soleus muscle in late stance.

277 Other variables were significantly different in IC gait but only when not accounting for walking speed.

278 Ankle power absorption in early stance, internal knee flexion at initial contact, knee power absorption in
279 mid-stance and late stance, internal extension moment in early stance and the internal flexion moment
280 in late stance, increase in maximum EMG activity of lateral gastrocnemius, and all ground reaction forces

281 all ceased to be statistically significant. This highlights the importance of changes in walking speed on gait
282 in this clinical group.

283

284 In accordance with previous literature the maximum internal ankle plantarflexion moment was reduced
285 in late stance in individuals with IC [11-12]. This agrees with Koutakis et al who tested unilateral [12] and
286 bilateral cases [11] and thus the change in internal plantarflexion moment seems independent of uni/bi
287 lateral nature of the arterial disease. Along with the reduced step length (table 1), ankle power generation
288 and absorption throughout stance, and second peak in vertical GRF, this result indicates a reduction in
289 internal force production in propulsion, specific to the calf muscles. This is further supported by the
290 reduction in soleus EMG (>19%). This concurs with the clinical presentation of pain in the calf because
291 insufficient blood and oxygen supply would lead to impaired muscle function and force production. The
292 soleus has been found to have a significantly higher percentage of type I or slow twitch muscle fibres
293 (70%) than the gastrocnemius (50%) [25-26]. These muscle fibres are more resistant to fatigue but
294 produce weaker contractions than fast twitch (type II) muscle fibres. Furthermore, in the calf muscle of
295 those with IC, the percentage of slow twitch (type I) muscle fibres is increased, compared to healthy
296 controls [27-28]. This would mean a further increase in the slow twitch muscle fibres in the soleus, which
297 would, in turn, reduce its peak force production.

298 Individuals with IC walked with 2.9 times their mean soleus activity compared to 3.6 for healthy
299 counterparts. This effect was not due to speed but could perhaps relate to the reduced step length (-
300 12.7%), since this would reduce the external forces and external joint moments the soleus opposes.
301 However, any effects of step length would logically affect all plantarflexor muscles and a similar reduction
302 was not found for the medial or lateral gastrocnemius. This selective effect could relate to the greater
303 percentage of type I fibres in the soleus muscles [26-28] which would reduce its peak force production
304 disproportionately compared to gastrocnemius.

305 The important reduction in ankle moments may be caused by the low walking speed in individuals with
306 IC. Indeed, Wurdeman et al [8] found no such difference when they compared individuals with IC who
307 walked at the same speed as healthy controls. However, the average speed of individuals with IC in
308 Wurdeman's study was considerably higher than that of individuals with IC in other studies, including the
309 present one. Although IC severity was not described, the higher walking speeds reported suggest that the
310 IC was less severe than in this and previous studies. This would also explain the absence of significant
311 difference in internal ankle plantarflexion moment in late stance. Furthermore, recognising that people

312 with IC do walk slower due to their generally poorer health and arterial disease status, the current study
313 sought to account for the effect of walking speed statistically. Most changes at the ankle remained
314 significant even accounting for speed and are thus related to the effects of IC.

315 Adjustments in walking speed, step length and calf muscle contraction could be concurrent strategies to
316 reduce the demand for oxygen in the calf musculature and increase pain free walking distance. Muscle
317 degeneration is present in individuals with IC [29] and this, coupled with the aforementioned change in
318 muscle fibre type, would reduce force generating capacity. This is supported by previous findings of
319 reduced peak isokinetic and concentric ankle torque produced by the calf muscles in individuals with IC
320 [30,31]. This reduced physiological capacity may lead to a shorter step length since propulsion is less
321 effective but also because it will reduce the external ankle dorsiflexion moments in late stance that the
322 calf muscles must overcome. Ultimately there are a range of approaches that the body might adopt to
323 better match muscle work done with muscle oxygen supply and thereby sustain pain free walking for
324 longer.

325 The reduction in internal flexion moment at the knee at initial contact, internal extension moment at the
326 hip in early stance, and reduced power absorption at both joints, indicate that individuals with IC have
327 reduced eccentric function of the quadriceps. Likewise, the reduced power production in mid-stance,
328 indicates a reduced effectiveness of the quadriceps to concentrically contract and support movement of
329 the femur over the tibia. Similar to the results for calf muscles, this suggests reduced capacity of lower
330 limb musculature in people with IC, as supported by similar literature findings in kinetics [11,31] and lower
331 muscle strength in knee flexion (-14.0%) [31].

332 Peripheral arterial disease is a multilevel and multi-stage disease and this may lead to different gait
333 effects. Changes at the level of the ankle are however almost unanimous across studies and different IC
334 categories. This is perhaps not surprising given that the calf muscles act mainly around the ankle and this
335 is the location of the clinical presentation.

336 Overall, findings suggest that if footwear or orthotic interventions are to benefit those with IC, they must
337 affect external moments so that the force required by the calf muscles can be reduced. A study on the
338 effect of orthotics and footwear on gait has explored the possibility of altering ankle moments and calf
339 muscle activity [32]. Many studies have also assessed the effect of footwear as a calf muscle exercise tool
340 [33-37]. Further research would be needed to investigate a footwear design with the potential to assist in
341 the management of IC gait.

342 Limitations

343 4. Limitations

344

345 There are a range of limitations to this study that need to be considered. The sample size of the study was
346 lower compared to other similar studies due to difficulty in recruitment. However, post-hoc power
347 calculations (G*power) for the main outcome measures of ankle moment and ankle power indicated
348 powers of 0.84 and 0.98 respectively, which are sufficient to support the findings. Sample size for EMG
349 data was small and potentially not sufficient to detect changes at the calf muscles. This said, the significant
350 findings for the soleus muscle activity, despite the low sample size, alongside the kinetic data, suggest
351 intrinsic structural changes to the muscle lead to loss of force generating capacity. These changes are
352 corroborated by previous research [31].

353

354 Furthermore, both individuals with unilateral and bilateral claudication were included in this study and
355 this assumes gait effects are consistent between the two. However, the current research design is
356 consistent with previous studies [7-8] and the purpose of this study was to investigate differences in gait
357 in the wider IC population rather than focus on sub-populations.

358 Similarly, in the present study, participants were not chosen according to occlusion level. The level of
359 occlusion has been shown to affect severity of patient symptoms and can significantly affect gait
360 parameters. However, this study was part of a larger study on individuals with PAD-IC with a clinical focus
361 on footwear to reduce symptoms. Therefore, it was deemed more appropriate to include participants of
362 all occlusion levels but of the same scale of pain.

363 All participants wore Oxford style shoes. While this is not a limitation, the shoes were not those habitually
364 worn by participants which could have affected their gait. This is standard practice in gait studies and
365 ensures that gait patterns are not subject to the effects of the wide array of shoe types worn by
366 participants.

367

368 5. Conclusion

369 People with IC walk slower and with reduced step length. There are reductions in ankle plantarflexion
370 moments and power generation that are consistent with reduced soleus EMG activity and reduced peak
371 vertical ground reaction forces during late stance. These effects are not due to reduced walking speed.
372 There are also changes in knee moments and power indicative of reduced quadriceps capacity and
373 reduced hip power absorption, which are unrelated to reduced walking speed. These outcomes provide a
374 platform for the design and evaluation of interventions that seek to restore normal walking and improve
375 pain free walking distances for this clinical population.

376

377 Acknowledgements

378

379 We would like to thank the Wrightington, Wigan and Leigh NHS Foundation Trust for partly funding this
380 research.

381 6. References

- 382 [1] SONG, P., RUDAN, D., ZHU, Y., FOWKES, F. J. I., RAHIMI, K., FOWKES, F. G. R., & RUDAN, I. (2019). Global,
383 regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated
384 systematic review and analysis. *The Lancet Global Health*, 7(8), e1020–e1030.doi:10.1016/s2214-
385 109x(19)30255-4
- 386 [2] WATSON, K., WATSON, B. D. & PATER, K. S. (2006). Peripheral Arterial Disease: A Review of Disease
387 Awareness and Management. *The American Journal of Geriatric Pharmacotherapy*, 4, 365-379.
- 388 [3] STEFFEN, L. M., DURPEZ D.A., BOUCHER, J. L., ERSHOW A., HIRSCH, A. T. (2008). Management of
389 Peripheral Arterial Disease. *Diabetes Spectrum*, 21(3): 171-177.
390 <https://doi.org/10.2337/diaspect.21.3.171>
- 391 [4] LILES, D., KALLEN, M., PETERSEN, L. and BUSH, R. (2006). Quality of Life and Peripheral Arterial
392 Disease. *Journal of Surgical Research*, 136(2), pp.294-301.
- 393 [5] CREASY, T. S., MCMILLAN, P. J., FLETCHER, E. W., COLLIN, J. & MORRIS, P. J. (1990). Is percutaneous
394 transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective
395 randomised trial. *Eur J Vasc Surg*, 4, 135-40.
- 396 [6] EBERHARDT, R. & COFFMAN, J. (2003). Clinical Evaluation of Intermittent Claudication. In: COFFMAN,
397 J. & EBERHARDT, R. (eds.) *Peripheral Arterial Disease*. Humana Press.
- 398 [7] CELIS, R., PIPINOS, I. I., SCOTT-PANDORF, M. M., MYERS, S. A., STERGIOU, N. & JOHANNING, J. M.
399 (2009). Peripheral arterial disease affects kinematics during walking. *Journal of Vascular Surgery*, 49, 127-
400 132.
- 401 [8] WURDEMAN, S. R., KOUTAKIS, P., MYERS, S. A., JOHANNING, J. M., PIPINOS, I. I. & STERGIOU, N. (2012).
402 Patients with peripheral arterial disease exhibit reduced joint powers compared to velocity-matched
403 controls. *Gait & Posture*, 36, 506-509.
- 404 [9] CROWTHER, R. G., SPINKS, W. L., LEICHT, A. S., QUIGLEY, F. & GOLLEDGE, J. (2007). Relationship
405 between temporal-spatial gait parameters, gait kinematics, walking performance, exercise capacity, and
406 physical activity level in peripheral arterial disease. *Journal of Vascular Surgery*, 45, 1172-1178.

407 [10] CHEN, S.-J., PIPINOS, I., JOHANNING, J., RADOVIC, M., HUISINGA, J. M., MYERS, S. A. & STERGIU, N.
408 (2008). Bilateral claudication results in alterations in the gait biomechanics at the hip and ankle joints.
409 *Journal of biomechanics*, 41, 2506-2514.

410 [11] KOUTAKIS, P., JOHANNING, J. M., HAYNATZKI, G. R., MYERS, S. A., STERGIU, N., LONGO, G. M. &
411 PIPINOS, I. I. (2010a). Abnormal joint powers before and after the onset of claudication symptoms. *Journal*
412 *of Vascular Surgery*, 52, 340-347.

413 [12] KOUTAKIS, P., PIPINOS, I. I., MYERS, S. A., STERGIU, N., LYNCH, T. G. & JOHANNING, J. M. (2010b).
414 Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral
415 claudication. *Journal of Vascular Surgery*, 51, 80-88.

416 [13] GOMMANS, L. N. M., SMID, A. T., SCHELTINGA, M. R. M., BROOIJMANS, F. A. M., VAN DISSELDORP,
417 E. M. J., VAN DER LINDEN, F. T. P. M., MEIJER, K. & TEIJINK, J. A. W. (2016). Altered joint kinematics and
418 increased electromyographic muscle activity during walking in patients with intermittent claudication.
419 *Journal of Vascular Surgery*, 63, 664-672.

420 [14] KING, S., VANICEK, N. and O'BRIEN, T., (2015). Dynamic muscle quality of the plantar flexors is
421 impaired in claudicant patients with peripheral arterial disease and associated with poorer
422 walking endurance. *Journal of Vascular Surgery*, 62(3), pp.689-697.

423 [15] BARTOLO, E., THORNE, C., GATT, A., FORMOSA C., (2019). The influence of peripheral arterial
424 disease on lower limb surface myoelectric signals in patients living with type II diabetes mellitus. *Gait*
425 *and Posture*, 73, pp.228-232

426 [16] PETERSON, M. J., PERRY, J. & MONTGOMERY, J. (1985). Walking patterns of healthy subjects wearing
427 rocker shoes. *Phys Ther*, 65, 1483-9.

428 [17] VAN BOGART, J. J., LONG, J. T., KLEIN, J. P., WERTSCH, J. J., JANISSE, D. J. & HARRIS, G. F. (2005). Effects
429 of the toe-only rocker on gait kinematics and kinetics in able-bodied persons. *IEEE Trans Neural*
430 *SystRehabil Eng*, 13, 542-50.

431 [18] HARDMAN, R.L., JAZAERI, O., Yi, J., SMITH, M., GUPTA, R. (2014). Overview of classification systems
432 in peripheral artery disease. *Semin Intervent Radiol*, 31(4):378-88.

433 [19] HERMENS H.J, M. R., RAU, G., DISSELHORST-KLUG, C., STEGEMAN, D.F., AND HÄGG, G.M., (2008).
434 SENIAM Project [Internet] 2008. [<http://www.seniam.org>].

435 [20] CAPPOZZO, A., CAPPELLO, A., DELLA CROCE, U. & PENSALFINI, F. (1997). Surface-marker cluster design
436 criteria for 3-D bone movement reconstruction. *IEEE Trans Biomed Eng*, 44, 1165-74.

437 [21] BELL, A.L., BRAND, R.A., PEDERSEN, D.R., (1989). Prediction of hip joint centre location from external
438 landmarks. *Hum Mov Sci.*; 8:3–16.

439 [22] GROOD, E.S., and SUNTA, W.J., (1983). A joint coordinate system for the clinical description of three-
440 dimensional motions: application to the knee. *Journal of Biomechanical Engineering*, 105(2), pp.136–144.

441 [23] DE LUCA, C. (1997). The Use of Surface Electromyography in Biomechanics. *Journal of Applied*
442 *Biomechanics*, 13(2), pp.135-163.

443 [24] BURDEN, A., & BARLETT, R. (1999). Normalisation of EMG amplitude: an evaluation and comparison
444 of old and new methods. *Medical Engineering & Physics*, 21(4), 247–257. doi:10.1016/s1350-
445 4533(99)00054-5

446 [25] EDGERTON, V. R., SMITH, J. L. & SIMPSON, D. R. (1975). Muscle fibre type populations of human leg
447 muscles. *Histochem J*, 7, 259-66.

448 [26] YANG, J.C., and YOO, J.Y., (1986) “Histochemical Muscle Fiber Types of Autopsied Human
449 Gastrocnemius, Soleus, Peroneus longus and Tibialis anterior Muscles.,” *The Korean Journal of*
450 *Pathology*,20(4),pp.413–426.Available at: <https://www.jpatholm.org/journal/view.php?number=615>.

451 [27] REGENSTEINER, J. G., WOLFEL, E. E., BRASS, E. P., CARRY, M. R., RINGEL, S. P., HARGARTEN, M. E.,
452 STAMM, E. R. & HIATT, W. R. (1993). Chronic changes in skeletal muscle histology and function in
453 peripheral arterial disease. *Circulation*, 87, 413-421.

454 [28] ENGLAND, J. D., REGENSTEINER, J. G., RINGEL, S. P., CARRY, M. R. & HIATT, W. R. (1992). Muscle
455 denervation in peripheral arterial disease. *Neurology*, 42, 994-9.

456 [29] MCGRAE MCDERMOTT, M., GURALNIK, J. M., FERRUCCI, L., TIAN, L., PEARCE, W. H., HOFF, F., LIU, K.,
457 LIAO, Y. & CRIQUI, M. H. (2007). Physical activity, walking exercise, and calf skeletal muscle characteristics
458 in patients with peripheral arterial disease. *Journal of Vascular Surgery*, 46, 87-93.

459 [30] BASYCHES, M., WOLOSKER, N., RITTI-DIAS, R. M., CAMARA, L. C., PUECH-LEAO, P. & BATTISTELLA, L.
460 R. (2009). Eccentric strength and endurance in patients with unilateral intermittent claudication. *Clinics*
461 (Sao Paulo), 64, 319-22.

462 [31] CÂMARA, L. C., RITTI-DIAS, R. M., MENÊSES, A. L., D'ANDRÉA GREVE, J. M., FILHO, W. J., SANTARÉM,
463 J. M., FORJAZ, C. L. D. M., PUECH-LEÃO, P. & WOLOSKER, N. (2012). Isokinetic Strength and Endurance in
464 Proximal and Distal Muscles in Patients With Peripheral Artery Disease. *Annals of Vascular Surgery*, 26,
465 1114-1119.

466 [32] OWEN, E. (2010). The importance of being Earnest about Shank and thigh Kinematics especially
467 When using Ankle-Foot Orthoses, *Prosthetics and orthotics International*, 34, 254-269.

468 [33] SACCO, I. C. N., SARTOR, C. D., CACCIARI, L. P., ONODERA, A. N., DINATO, R. C., PANTALEÃO JR, E.,
469 MATIAS, A. B., CEZÁRIO, F. G., TONICELLI, L. M. G., MARTINS, M. C. S., YOKOTA, M., MARQUES, P. E. C. &
470 COSTA, P. H. C. (2012). Effect of a rocker non- heeled shoe on EMG and ground reaction forces during
471 gait without previous training. *Gait & Posture*, 36, 312-315.

472 [34] SOUSA, A., TAVARES, J. M. R. S., MACEDO, R., RODRIGUES, A. M. & SANTOS, R. (2012). Influence of
473 wearing an unstable shoe on thigh and leg muscle activity and venous response in upright standing.
474 *Applied Ergonomics*, 43, 933-939.

475 [35] BUCHECKER, M., WAGNER, H., PFUSTERSCHMIED, J., STOGGL, T. L. & MULLER, E. (2012). Lower
476 extremity joint loading during level walking with Masai barefoot technology shoes in overweight males.
477 *Scand J Med Sci Sports*, 22, 372-80.

478 [36] HORSACK, B. & BACA, A. (2013). Effects of toning shoes on lower extremity gait biomechanics.
479 *Clinical Biomechanics*, 28, 344-349.

480 [37] TURBANSKI, S., LOHRER, H., NAUCK, T. & SCHMIDTBLEICHER, D. (2011). Training effects of two
481 different unstable shoe constructions on postural control in static and dynamic testing situations.
482 *Physical Therapy in Sport*, 12, 80-86.

483

484

485

486

487

488

489

490 Tables

	IC	Healthy	<i>P</i> value
Male	12	11	n/a
Female	6	7	n/a
Mean Age (yrs)	67.5(7.9)	61.3 (5.1)	0.246
Mean Height (m)	1.70 (SD = 0.08)	1.65 (SD = 0.08)	0.422
Mean Mass (kg)	75.3 (SD = 12.4)	69.2 (SD = 10.6)	0.182
Mean Walking Speed (m/s)	1.00 (SD = 0.25)	1.25 (SD = 0.23)	<0.001
Step length (m)	0.62 (SD = 0.07)	0.71 (SD = 0.13)	0.019
Diabetes	2	n/a	n/a
Unilateral claudication	7	n/a	n/a
Bilateral claudication	11	n/a	n/a

491 Table 1: Participant demographics and temporal-spatial parameters.

492

493

494 Table 2: Mean, standard deviation and *P* values for ankle angle (°), ankle moment (Nm/Kg) and
 495 ankle power (W/Kg) in IC and healthy groups. * = Significant difference when adjusted for
 496 speed.

Outcome measure	IC		Healthy		<i>P</i>	<i>Adjusted P</i>
	Mean	SD	Mean	SD		
Max ankle plantarflexion (°)	-5.69	2.82	-7.23	2.29	0.081	>0.05
Max ankle dorsiflexion (°)	-19.5	3.14	-18.9	3.18	0.559	>0.05
Max internal ankle dorsiflexion moment early stance (Nm/Kg)	0.25	0.11	0.28	0.06	0.271	>0.05
Max internal ankle plantarflexion moment late stance (Nm/Kg)	1.15	0.56	1.55	0.14	0.004*	0.030
Max ankle power absorption early stance (W/Kg)	-0.55	0.26	-0.76	0.25	0.018	>0.05

Max ankle power absorption mid-stance (W/Kg)	-1.29	0.27	-1.57	0.66	0.112	>0.05
Max ankle power generation late stance (W/Kg)	1.90	0.49	2.80	0.80	<0.001*	p =0.022

497

498

499 Table 3: Mean peaks, standard deviation and *P* values for knee angle (°), knee moment (Nm/Kg)
500 and knee power (W/Kg) in IC and healthy groups.

501

* = Significant differences when adjusted for speed.

502

Outcome measure	IC		Healthy		<i>P</i>	<i>Adjusted P</i>
	Mean	SD	Mean	SD		
Max knee flexion early stance (°)	15.29	5.31	16.99	5.46	0.81	>0.05
Max knee extension (°)	3.13	4.66	3.10	5.71	0.559	>0.05
Max internal knee flexion moment initial stance (Nm/Kg)	-0.18	0.08	-0.25	0.08	0.009	>0.05
Max internal knee extension moment early stance (Nm/Kg)	0.50	0.22	0.59	0.19	0.184	0.030
Max internal knee flexion moment late stance (Nm/Kg)	-0.30	0.12	-0.33	0.11	0.354	>0.05
Max internal knee extension moment terminal stance (Nm/Kg)	0.15	0.06	0.18	0.06	0.136	>0.05
Max knee power absorption early stance (W/Kg)	-0.54	0.40	-1.03	0.38	0.001*	0.022
Max knee power generation (W/Kg)	0.53	0.22	0.52	0.26	0.047	0.030
Max knee power generation mid-stance (W/Kg)	0.40	0.13	0.49	0.23	0.147	>0.05
Max knee power absorption late stance (W/Kg)	-0.81	0.33	-1.15	0.31	0.002	>0.05

503

504

505

506

507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517

Table 4: Mean peaks, standard deviation and *P* values for hip angle (°), hip moment (Nm/Kg) and hip power (W/Kg) in IC and healthy groups. * = Significant differences when adjusted for speed.

Outcome measure	IC		Healthy		<i>P</i>	<i>Adjusted P</i>
	Mean	SD	Mean	SD		
Max hip flexion (°)	34.87	9.67	35.17	8.33	0.922	>0.05
Max hip extension (°)	-5.66	11.47	-6.55	10.65	0.810	>0.05
Max internal hip extension moment early stance (Nm/Kg)	-0.55	0.16	-0.74	0.25	0.012	>0.05
Max internal hip flexion moment late stance (Nm/Kg)	0.61	0.19	0.77	0.25	0.032	0.030
Max hip power generation early stance (W/Kg)	0.52	0.26	0.85	0.53	0.022	>0.05
Max hip power absorption early stance (W/Kg)	-0.09	0.22	-0.52	0.28	<0.001*	<0.001
Max hip power generation late stance (W/Kg)	0.98	0.35	1.18	0.43	0.136	>0.05
Max hip power absorption late stance (W/Kg)	-0.62	0.44	-0.72	0.37	0.482	>0.05

518
 519
 520
 521
 522

Table 5: Mean, standard deviation and *P* value of peak EMG (expressed relative to each group's EMG mean) in IC and healthy groups. * = Significant differences when adjusted for speed

Outcome measure	IC	Healthy		
-----------------	----	---------	--	--

	Mean	SD	Mean	SD	<i>P</i>	<i>Adjusted P</i>
Tibialis anterior	2.94	0.74	3.37	0.56	0.112	>0.05
Medial Gastrocnemius	3.91	1.38	3.98	1.00	0.888	>0.05
Lateral Gastrocnemius	3.30	0.86	4.21	0.92	0.016	>0.05
Soleus	2.89	0.62	3.57	0.60	0.010*	0.026

523

524 Table 6: Mean peak, standard deviation and *P* value for GRF (*normalised to body weight) in IC
525 and healthy groups.

526 * = Significant differences when adjusted for speed.

527

Outcome measure	IC		Healthy		<i>P</i>	<i>Adjusted P</i>
	Mean	SD	Mean	SD		
Maximum posterior GRF early stance GRF <i>(*normalised to body weight)</i>	0.16	0.03	0.22	0.04	<0.001*	0.009
Maximum anterior GRF late stance GRF <i>(*normalised to body weight)</i>	-0.15	0.04	-0.20	0.03	<0.001*	0.005
Maximum lateral GRF early stance GRF <i>(*normalised to body weight)</i>	-0.03	0.02	-0.06	0.03	0.002*	p = 0.017
Maximum lateral GRF late stance GRF <i>(*normalised to body weight)</i>	-0.01	0.01	-0.01	0.01	0.193	>0.05
Maximum vertical GRF early stance GRF <i>(*normalised to body weight)</i>	1.08	0.09	1.16	0.15	0.045	>0.05
Minimum vertical GRF mid-stance GRF <i>(*normalised to body weight)</i>	0.78	0.04	0.74	0.12	0.170	>0.05
Maximum vertical GRF late stance GRF <i>(*normalised to body weight)</i>	1.06	0.06	1.17	0.1	<0.001*	0.004

528

529